PR Newswire (Tue, 2:16PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
834 people get DGX articles and Market Currents by email alert.
Get email alerts on DGX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Exclusive Services AgreementPR Newswire (May 16, 2013)
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 16, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 5, 2013)
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Mar 27, 2013)
-
Earnings Analysis: Quest Diagnostics Inc.CapitalCube • Thu, Oct 18, 2012
-
Quest Diagnostics, Inc: Fundamental Stock Research AnalysisF.A.S.T. Graphs • Wed, Oct 17, 2012
-
Insider Trading Report: Quest DiagnosticsInsider Monkey • Thu, Aug 9, 2012
-
Quest Diagnostics: Earnings PreviewZacks Investment Research • Wed, Apr 18, 2012
-
Investors Should Wait Out Quest And LabCorpPaul Nouri • Thu, Feb 16, 2012
-
Quest Diagnostics: Earnings PreviewZacks Investment Research • Sat, Jan 21, 2012
-
Quest Diagnostics Earnings PreviewZacks Investment Research • Mon, Oct 24, 2011
-
Quest Lowers Outlook, Announces Cost-Reduction PlanZacks Investment Research • Thu, Jul 21, 2011
-
Quest Diagnostics: Earnings PreviewZacks Investment Research • Mon, Jul 18, 2011
-
Quest Diagnostics Gains MomentumJim Van Meerten • Mon, Jun 20, 2011
-
Earnings Preview: Quest DiagnosticsZacks Investment Research • Mon, Jan 24, 2011
-
Quest Diagnostics Rallies on FDA Approval for Flu TestProactive Investor • Thu, Dec 2, 2010
-
Quest Diagnostics Earnings PreviewZacks Investment Research • Tue, Oct 19, 2010
-
Quest Diagnostics: Slower Growth Makes Investors TestyOckham Research • Mon, Jan 25, 2010
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
-
5 Significant Buys By Ziegler Capital ManagementEfsinvestment • Thu, Nov 22, 2012
-
Trovagene's Foray Into The Conventions Of Molecular DiagnosticsJ. King • Thu, Nov 15, 2012
-
Quest Diagnostics' CEO Hosts Investor Day (Transcript)Fri, Nov 16, 2012 • 1 Comment
-
Quest Diagnostics Inc Q2 2010 Earnings Call TranscriptWed, Jul 21, 2010
-
Quest Diagnostics Incorporated Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Quest Diagnostics Incorporated Q4 2009 Earnings Call TranscriptMon, Jan 25, 2010
-
Quest Diagnostics Inc., Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Quest Diagnostics Inc. Q2 2009 Earnings Call TranscriptTue, Jul 21, 2009 • 1 Comment
-
Quest Diagnostics Inc., Q1 2009 Earnings Call TranscriptTue, Apr 21, 2009
-
Quest Diagnostics Incorporated Q4 2008 Earnings Call TranscriptMon, Jan 26, 2009
-
Quest Diagnostics Inc. Q3 2008 Earnings Conference Call TranscriptTue, Oct 21, 2008
-
PR Newswire (Tue, 2:16PM)
-
Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Exclusive Services AgreementPR Newswire (May 16, 2013)
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 7, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 16, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 5, 2013)
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Mar 27, 2013)
DGX vs. ETF Alternatives
Company Description
Quest Diagnostics Incorporated is the world’s leading provider of diagnostic testing, information and services. We provide insights that enable patients, physicians and others to make better healthcare decisions.
Quest Diagnostics was incorporated in Delaware in 1990; its predecessor... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 2:40 PM Quest Diagnostics (DGX) declares $0.30/share quarterly dividend, in line with previous. Forward yield 1.95%. For shareholders of record July 2. Payable July 17. Ex-div date June 28. (PR) Comment! [Dividends]
- Thursday, May 16, 1:55 PM Quest Diagnostics (DGX +0.3%) moves to expand its lab business by acquiring the toxicology and clinical laboratory business of Concentra, a medical center operator owned by Humana (HUM). The business will be transitioned into DGX's national laboratory network of regional clinical and toxicology laboratories by the end of 2013. The the company also entered into a long-term agreement with Concentra to be its primary provider of workplace drug toxicology and clinical lab testing. Comment! [M&A, Healthcare]
- Wednesday, April 17, 9:52 AM More on Quest Diagnostics (DGX -0.8%) Q1: net profit -15% to $135.8M as operating margin falls to to 12.7% from 15.6%. Revenues from diagnostic information services -6.7%, requisitions volume -3.4%, and revenue per requisition -3.4%. Expects FY revenue to be similar to last year vs prior guidance of flat to growth of 1%. Agrees to acquire the lab-related clinical outreach service operations of Dignity Health for an undisclosed amount. (PR) Comment! [Healthcare, Earnings]
- Wednesday, April 17, 7:02 AM Quest Diagnostics (DGX): Q1 EPS of $0.89 misses by $0.15. Revenue of $1.8B (-6.4% Y/Y) misses by $0.06B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 17, 12:05 AM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
- Tuesday, April 16, 5:30 PM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
- Friday, April 12, 12:49 PM Lab Corp. (LH -1.8%) gives back yesterdays gains after being downgraded at WallachBeth Capital to Hold today on valuation. The stock was upgraded yesterday by Goldman, along with Quest Diagnostics (DGX -1.5%), on the sector's improving fundamentals. DGX appears to be giving back a little of the previous session's gain in sympathy as well. Comment! [Healthcare, On the Move]
- Thursday, April 11, 10:03 AM Goldman upgrades the Life Sciences Tools & Diagnostics sector to Attractive, but some individual names suffered as Mettler Toledo (MTD -2%) and Sigma-Aldrich (SIAL -1.1%) catch downgrades to Neutral from Buy. SIAL has "few levers to drive EBIT [as] long-term organic growth guidance of 4-6% is too high." Quest Diagnostics (DGX +3.5%) and LabCorp (LH +2%) are upgraded to Buy and Neutral respectively on the former's "untapped capital allocation potential and margin expansion" and the latter's ability to manage pricing pressure. Comment! [On the Move]
- Thursday, March 14, 1:20 PM Quest Diagnostics (DGX +1.2%) says that Chief Financial Officer Robert Hagemann is stepping down after 21 years at the company, effective May 31. The medical lab-testing firm has launched a search to find a successor, and will consider both internal and external candidates. Comment! [Healthcare, On the Move]
- Tuesday, February 26, 5:49 PM Quest Diagnostics Inc (DGX) declares $0.30/share quarterly dividend, in line with previous. Forward yield 2.15%. For shareholders of record Apr. 02. Payable Apr. 16. Ex-div date Mar. 29. (PR) Comment! [Dividends]
- Wednesday, January 23, 7:08 AM Quest Diagnostics (DGX): Q4 EPS of $1.01 misses by $0.05. Revenue of $1.77B (-4% Y/Y) misses by $0.06B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, January 23, 12:05 AM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 22, 5:30 PM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Wednesday, January 16, 8:40 AM Quest Diagnostics (DGX) will take a charge of $89.5M after saying it plans to sell its HemoCue diagnostic products business. Quest will write off the ops, along with its OralDNA unit, which it sold in December. Quest will restate 2012 and 2011 to remove the units from continuing ops. That will cut EPS by $0.09 and revenue by $117M. Superstorm Sandy has hurt Quest's Q4 EPS by $0.06 and its revenues by $21M. (PR) Comment! [Healthcare]
- Monday, December 31, 2012, 9:00 AM Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine. Comment! [Healthcare]
- Friday, November 16, 2012, 7:38 AM Quest Diagnostics (DGX) uses the occasion of an investor day to announce a quarterly dividend hike to $0.30/share fro $0.17 previously. The company also bumps its 2014 cost-savings commitment by $100M to $600M. "We are focusing on our core diagnostic information services business and on driving operational excellence." Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.














